WHO ICTRP trial
Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
JPRN-jRCT2031210431 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2031210431 |
|---|---|
| Public title | Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC |
| Scientific title | A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer - BLU-945-1101 |
| Primary sponsor | Zalutskaya Alena |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 1-2 |
| Countries | US;Japan;UK;Japan;Taiwan;Japan;Spain;Japan;South Korea;Japan;Singapore;Japan;Netherlands;Japan;Germany;Japan;France;Japan;Canada;Japan |
| Conditions | EGFR Mutant Non-Small Cell Lung Cancer |
| Interventions | Determined dose in each cohort is administered orally as BLU-945 monotheraphy or in combination with Osimertinib in each cohort/phase. |
| Registration date | Nov 19, 2021 |
| Target size | 19 |
| Secondary IDs | NCT04862780 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: